• 1
    Solomon DH, Morris C, Cheng H, Cabral D, Katz JN, Finkelstein JS, Avorn J 2005 Medication use patterns for osteoporosis: An assessment of guidelines, treatment rates and quality improvement interventions. Mayo Clin Proc 80: 194202.
  • 2
    Tosteson ANA, Grove MR, Hammond CS, Moncur MM, Ray GT, Hebert GM, Pressman AR, Ettinger B 2003 Early discontinuation of treatment for osteoporosis. Am J Med 115: 209216.
  • 3
    Papaioannou A, Ioannidis G, Adachi JD, Sebaldt RJ, Ferko N, Puglia M, Brown J, Tenenhouse A, Olszynski WP, Boulos P, Hanley DA, Josse R, Murray TM, Petrie A, Goldsmith CH 2003 Adherence to bisphosphonates and hormone replacement therapy in a tertiary care setting of patients in the CANDOO database. Osteoporos Int 14: 808813.
  • 4
    Elliot-Gibson V, Bogoch ER, Jamal SA, Beaton DE 2004 Practice patterns in the diagnosis and treatment of osteoporosis after a fragility fracture: A systematic review. Osteoporos Int 15: 767778.
  • 5
    Kanis JA, Johnell O, de Laet C, Johnasson H, Oden A, Delmas P, Eisman J, Fujiwara S, Garnero P, Kroger H, McCloskey EV, Mellstrom D, Melton LJ, Pols H, Reeve J, Silman A, Tenenhouse A 2004 A meta-analysis of previous fracture and subsequent fracture risk. Bone 35: 375382.
  • 6
    Jaglal SB, Weller I, Mamdani M, Hawker G, Kreder H, Jaakkimainen L, Adachi JD 2005 Population trends in bone density testing, treatment and hip and wrist fracture rates: Are the hip fracture projections wrong? J Bone Miner Res 20: 898905.
  • 7
    Chang JT, Morton SC, Rubenstein LZ, Mojica WA, Maglione M, Suttorp MJ, Roth EA, Shekelle PG 2004 Interventions for the prevention of falls in older adults: Systematic review and meta-analysis of randomised clinical trials. BMJ 328: 680683.
  • 8
    Kanis JA, Black D, Cooper C, Dargent P, Dawson-Hughes B, de Laet C, Delmas P, Eisman J, Johnell O, Jonsson B, Melton LJ III, Oden A, Papapoulos S, Pols H, Rizzoli R, Silman A, Tenenhouse A, On behalf of the International Osteoporosis Foundation and the National Osteoporosis Foundation USA 2002 A new approach to the development of assessment guidelines for osteoporosis. Osteoporos Int 13: 527536.
  • 9
    Cummings SR, Melton LJ III 2002 Epidemiology and outcomes of osteoporotic fractures. Lancet 359: 17611767.
  • 10
    United Nations Population Division 2003 World Population Prospects: The 2002 Revision Population Database. United Nations, New York, NY, USA.
  • 11
    Cooper C, Campion G, Melton LJ III 1992 Hip fractures in the elderly: A world-wide projection. Osteoporos Int 2: 285289.
  • 12
    Melton LJ III, O'Fallon WM, Riggs BL 1987 Secular trends in the incidence of hip fractures. Calcif Tissue Int 41: 5764.
  • 13
    Kannus P, Niemi S, Parkkari J, Palvanen M, Heinonen A, Sievänen H, Järvinen T, Khan K, Järvinen M 2002 Why is the age-standardized incidence of low-trauma fractures rising in many elderly populations? J Bone Miner Res 17: 13631367.
  • 14
    McClung MR, Geusens P, Miller PD, Zippel H, Bensen WG, Roux C, Adami S, Fogelman I, Diamond T, Eastell R, Meunier PJ, Reginster J-Y for the Hip Intervention Program Study Group 2001 Effect of risedronate on the risk of hip fracture in elderly women. N Engl J Med 344: 333340.
  • 15
    de Laet CEDH, van Hout BA, Burger H, Hofman A, Pols HAP 1997 Bone density and risk of hip fracture in men and women: Cross sectional analysis. BMJ 315: 221225.
  • 16
    Gullberg B, Johnell O, Kanis JA 1997 World-wide projections for hip fracture. Osteoporos Int 7: 407413.
  • 17
    Melton LJ, Atkinson EJ, Madhok R 1996 Downturn in hip fracture incidence. Public Health Rep 111: 146150.
  • 18
    Haas JS, Kaplan CP, Gerstenberger EP, Kerlikowske K 2004 Changes in the use of postmenopausal hormone therapy after the publication of clinical trial results. Ann Intern Med 140: 184188.
  • 19
    Riggs BL, Melton LJ III 2002 Bone turnover matters: The raloxifene treatment paradox of dramatic decreases in vertebral fractures without commensurate increases in bone density. J Bone Miner Res 17: 1114.
  • 20
    Kanis JA, Johnell O, Oden A, de Laet C, Jonsson B, Dawson A 2002 Ten-year risk of osteoporotic fracture and the effect of risk factors on screening strategies. Bone 30: 251258.
  • 21
    Melton LJ III, Amadio PC, Crowson CS, O'Fallon WM 1998 Long-term trends in the incidence of distal forearm fractures. Osteoporos Int 8: 341348.
  • 22
    Cuddihy M-T, Gabriel SE, Crowson CS, O'Fallon WM, Melton LJ III 1999 Forearm fractures as predictors of subsequent osteoporotic fractures. Osteoporos Int 9: 469475.
  • 23
    Ensrud KE, Barrett-Connor EL, Schwartz A, Santora AC, Bauer DC, Suryawanshi S, Feldstein A, Haskell WL, Hochberg MC, Torner JC, Lombardi A, Black DM, for the Fracture Intervention Trial Long-Term Extension Research Group 2004 Randomized trial of effect of alendronate continuation versus discontinuation in women with low BMD: Results from the Fracture Intervention Trial Long-Term Extension. J Bone Miner Res 19: 12591269.
  • 24
    Rose G 2001 Sick individuals and sick populations. Int J Epidemiol 30: 427432.
  • 25
    Stafford RS, Drieling RL, Hersh AL 2004 National trends in osteoporosis visits and osteoporosis treatment, 1988–2003. Arch Intern Med 164: 15251530.
  • 26
    Newman ED, Ayoub WT, Starkey RH, Diehl JM, Wood GC 2003 Osteoporosis disease management in a rural health care population: Hip fracture reduction and reduced costs in postmenopausal women after 5 years. Osteoporos Int 14: 146151.
  • 27
    Caro JJ, Ishak KJ, Huybrechts KF, Raggio G, Naujoks C 2004 The impact of compliance with osteoporosis therapy on fracture rates in actual practice. Osteoporos Int 15: 10031008.